A federal class-action lawsuit filed in South Carolina has accused the National Association of Realtors (NAR) and real estate giant Keller Williams Realty of violating federal antitrust laws. The suit alleges that this violation led to the artificial inflation of home prices in the state, per Yahoo News.
This legal action follows a recent case in Missouri where a jury verdict held the NAR accountable for illegal agreements with some of the nation’s largest real estate brokerage firms. The jury determined that these agreements resulted in $1.79 billion in losses for home sellers in Missouri. The damages in that case could potentially reach up to $5.3 billion, as “treble” or triple damages are being considered.
Among the co-defendants in the Missouri case were Keller Williams, Berkshire Hathaway’s HomeServices of America (formerly Century 21 Sweyer and Associates), RE/MAX, and Anywhere (formerly Realogy). Notably, Anywhere Real Estate and RE/MAX reached a $138 million settlement prior to the verdict.
Read more: DOJ Wants National Association Of Realtors Probe Revived
The South Carolina lawsuit, filed on Monday, seeks class-action status on behalf of all home sellers in the state who utilized a listing broker affiliated with Keller Williams and listed their homes on one of the NAR’s Multiple Listing Services (MLS) since November 2019. This move suggests a widening scope for legal scrutiny into alleged antitrust practices within the real estate industry.
As both cases unfold, the real estate landscape may witness significant shifts in the wake of these legal challenges.
Source: Finance Yahoo
Featured News
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Lina Khan to Step Down as FTC Chair in the Coming Weeks
Jan 21, 2025 by
CPI
Trump’s Executive Actions Signal a New Era for Cryptocurrency Regulation
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan